-- 根據FactSet調查的分析師數據，應用材料公司（AMAT）的平均評級為“買入”，平均目標價為435.13美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Related Articles
Mining & Metals
Troilus Mining Upsizes Debt Financing Mandate for up to US$1.2 Billion
Troilus Mining (TLG.TO) increased its previously announced debt financing mandate from up to US$1.0 billion to up to US$1.2 billion.The upsizing reflects "continued strong lender support and advancing progress toward a fully funded construction package for the Troilus copper-gold project, located in north-central Quebec, Canada," it said.The financing is being led by a syndicate of leading global financial institutions, including Societe Generale, KfW IPEX-Bank, and Export Development Canada, and is expected to form the cornerstone of the project's overall financing structure, the company added.Shares of the company closed down 1.2% to $1.59 on Monday on the Toronto Stock Exchange.
$TLG.TO
Australia
IPG Photonics' Q1 Adjusted Earnings Decline, Revenue Increases; Q2 Outlook Issued; Shares Drop Pre-Bell
IPG Photonics (IPGP) reported Q1 adjusted earnings Tuesday of $0.29 per diluted share, down from $0.31 a year earlier.An analyst polled by FactSet expected $0.31.Revenue for the quarter ended March 31 was $265.5 million, compared with $227.8 million a year earlier.An analyst polled by FactSet expected $265.5 million.The company expects Q2 adjusted EPS of $0.25 to $0.55 and $260 million to $290 million in revenue. Analysts polled by FactSet expect $0.44 in adjusted EPS on revenue of $275.7 million.Separately, IPG Photonics said it agreed on a global settlement with TRUMPF Laser- und Systemtechnik to resolve and close their patent dispute. No other details were disclosed.Shares of IPG Photonics were down more than 17% premarket Tuesday.Price: $100.60, Change: $-21.73, Percent Change: -17.76%
$IPGP
Research
Research Alert: Idexx Posts Solid Q1 Fueled By Innovation And Strong Cag Group Performance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IDEXX posted strong Q1 results with EPS of $3.47 (+17% Y/Y), beating expectations by $0.06, while revenue reached $1.141B (+14% Y/Y), $30M above consensus. CAG Diagnostics recurring revenue grew 14% Y/Y to $920M, demonstrating resilient demand for core diagnostic solutions. Operating margin expanded 10 bps to 31.8%, supported by strong recurring revenue gains and operational productivity initiatives. International markets showed particular strength with CAG revenue growing 22.7% compared to 11% domestically, highlighting successful global expansion efforts, in our view. The 12% expansion in the global premium instrument installed base and 20% growth in VetLab consumables underscore continued innovation adoption. Management raised the full-year 2026 guidance, reflecting confidence in the business trajectory, in our view: IDXX sees 2026 sales in the range of $4.675B-4.760B vs. prior $4.632B-$4.720B, representing +8.6%-10.6% Y/Y growth and EPS of $14.45-$14.90 vs. prior $14.29-$14.80, reflecting +11%-14% Y/Y.
$IDXX